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RESEARCH ARTICLE Open Access
Evaluation of etoricoxib in patients undergoing
total knee replacement surgery in a double-blind,
randomized controlled trial
Narinder Rawal1*, Eugene Viscusi2, Paul M Peloso3, Harold S Minkowitz4, Liang Chen5, Sandhya Shah3,
Anish Mehta6, Denesh K Chitkara3, Sean P Curtis3 and Dimitris A Papanicolaou3
Abstract
Background: Optimal postoperative pain management is important to ensure patient comfort and early mobilization.
Methods: In this double-blind, placebo- and active-controlled, randomized clinical trial, we evaluated postoperative
pain following knee replacement in patients receiving placebo, etoricoxib (90 or 120 mg), or ibuprofen 1800 mg daily
for 7 days. Patients ≥18 years of age who had pain at rest ≥5 (0–10 Numerical Rating Scale [NRS]) after unilateral total
knee replacement were randomly assigned to placebo (N = 98), etoricoxib 90 mg (N = 224), etoricoxib 120 mg (N = 230),
or ibuprofen 1800 mg (N = 224) postoperatively. Co-primary endpoints included Average Pain Intensity Difference at
Rest over Days 1–3 (0- to 10-point NRS) and Average Total Daily Dose of Morphine over Days 1–3. Pain upon
movement was evaluated using Average Pain Intensity Difference upon Knee Flexion (0- to 10-point NRS). The primary
objective was to demonstrate analgesic superiority for the etoricoxib doses vs. placebo; the secondary objective was to
demonstrate that the analgesic effect of the etoricoxib doses was non-inferior to ibuprofen. Adverse experiences (AEs)
including opioid-related AEs were evaluated.
Results: The least squares (LS) mean (95% CI) differences from placebo for Pain Intensity Difference at Rest over Days
1–3 were −0.54 (−0.95, −0.14); −0.49 (−0.89, −0.08); and −0.45 (−0.85, −0.04) for etoricoxib 90 mg, etoricoxib 120 mg,
and ibuprofen, respectively (p < 0.05 for etoricoxib vs. placebo). Differences in LS Geometric Mean Ratio morphine use
over Days 1–3 from placebo were 0.66 (0.54, 0.82); 0.69 (0.56, 0.85); and 0.66 (0.53, 0.81) for etoricoxib 90 mg, etoricoxib
120 mg, and ibuprofen, respectively (p < 0.001 for etoricoxib vs. placebo). Differences in LS Mean Pain Intensity upon
Knee Flexion were −0.37 (−0.85, 0.11); −0.46 (−0.94, 0.01); and −0.42 (−0.90, 0.06) for etoricoxib 90 mg, etoricoxib
120 mg, and ibuprofen, respectively. Opioid-related AEs occurred in 41.8%, 34.7%, 36.5%, and 36.3% of patients on
placebo, etoricoxib 90 mg, etoricoxib 120 mg, and ibuprofen, respectively.
Conclusions: Postoperative use of etoricoxib 90 and 120 mg in patients undergoing total knee replacement is
both superior to placebo and non-inferior to ibuprofen in reducing pain at rest and also reduces opioid
(morphine) consumption.
Clinical trial registration: NCT00820027
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Background
Total knee replacement surgery is an option taken by
patients who suffer from debilitating pain and loss of
function, in association with demonstrated loss of cartil-
age due to a variety of conditions, but most commonly
associated with osteoarthritis. The procedure has estab-
lished efficacy and provides pain relief as well as func-
tional improvement [1-3]. Additionally, the frequency of
this procedure is increasing in the Western world as
the population ages and the prevalence of osteoarthritis
rises [4,5].
Postoperative pain management serves several goals
including reduction of suffering and improvement of
recovery. After the initial immediate postoperative period,
good pain management also improves quality of life
and satisfaction with the procedure [6]. Multimodal
pain management strategies that maximize pain relief
while minimizing tolerability issues such as opioid-
related adverse events (AEs) are recommended post-
operatively through the modulation of several pain
pathways at lower doses than would be required if a
single pathway were targeted [7-10]. Although non-
steroidal anti-inflammatory drugs (NSAIDs) provide
good complementary effects for pain relief when com-
bined with opioids in multimodal analgesia regimens,
guidelines and common practice generally recommend
patients discontinue them. These recommendations
are due to the inhibition of cyclo-oxygenase (COX)-1
by traditional NSAIDs, which has been shown to
interfere with platelet aggregation and can thus lead
to the possibility of increased bleeding in surgical
settings.
The present study evaluates the use of etoricoxib, a
selective COX-2 inhibitor, as part of a multimodal an-
algesic treatment in total knee replacement surgery
patients. Etoricoxib has demonstrated efficacy in many
painful conditions, including a previous study that
demonstrated efficacy in patients undergoing total knee
or hip arthroplasty [11]. Its pharmacokinetic profile
shows a lack of effect on COX-1, and, therefore, it
has minimal effects on platelet aggregation [12] mak-
ing it an appropriate treatment in surgical settings in
contrast to traditional NSAIDs such as ibuprofen.
This study provides additional information on the
efficacy and safety of etoricoxib in a large patient
sample treated for 7 days postoperatively and fol-
lowed for 21 days after the first dose; two doses of
etoricoxib (90 and 120 mg) were evaluated against
both an active comparator (ibuprofen) and placebo,
as well as assessing both static pain and pain on
movement. The hypothesis of this trial was that etori-
coxib 90 and 120 mg would provide superior efficacy
compared with placebo and would be non-inferior
to ibuprofen.
Methods
This study (Sponsor Protocol #098) was registered at
clinicaltrials.gov (NCT00820027). It was conducted at
63 sites globally, including in the United States (13 sites);
Europe (41 sites, includes Bulgaria, Czech Republic,
Estonia, Germany, Hungary, Lithuania, Norway, Serbia,
Slovenia, South Africa and Turkey); Costa Rica (1 site);
and Asia Pacific (8 sites, includes Philippines, South Korea,
Singapore and Taiwan) from December 30, 2008 to
December 13, 2010. All patients gave written informed
consent prior to initiation of the study, and the proto-
col and all amendments were approved by local insti-
tutional review boards (IRBs). The specific institutional
review boards that approved the study are provided in
(Additional file 1). The study was conducted in accord-
ance with the principles of Good Clinical Practice and ap-
plicable country and/or local statutes and regulations.
Patients
Eligible patients were men and women, at least 18 years
of age, considered to be in good general health, and
scheduled to have a unilateral total knee replacement
completed in 3 hours or less. Chronic, stable health con-
ditions were permitted. Women of childbearing potential
were required to have a β-hCG consistent with a non-
gravid state prior to randomization and were then re-
quired to use adequate birth control methods or remain
abstinent during the study. Post-operatively, patients
needed to tolerate clear liquids and have a pain intensity
of ≥5 (0- to 10-point numerical rating scale [NRS] where
0 = no pain and 10 = pain as bad as you can imagine) in
the recovery room.
Patients were excluded if they were allergic or intolerant
to study medications; had a recent history of chronic drug
abuse/dependence; had received an investigational agent/
device (within 4 weeks); or were morbidly obese. Patients
with certain cardiovascular (uncontrolled hypertension,
congestive heart failure, history of coronary artery by-
pass graft surgery, angioplasty, cerebrovascular accident
or transient ischemic attack) and gastrointestinal condi-
tions (gastric ulcer, gastric surgery, or inflammatory
bowel disease) were also excluded.
Study design
This was a randomized, double-blind, placebo- and active-
comparator-controlled, multiple-dose study performed
under in-house blinding in patients undergoing unilat-
eral total knee replacement surgery to evaluate the tol-
erability and efficacy of etoricoxib. The first dose of study
medicine (oral etoricoxib 120 mg, etoricoxib 90 mg, ibu-
profen dose of 600 mg or placebo) was administered post-
operatively in the recovery room and prior to 6 p.m. on
the day of surgery. To maintain the blinding, all therapies
were given 3 times a day (with 1 active dose of etoricoxib
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and 2 doses of placebo), to mimic the total daily dosing
frequency of ibuprofen.
At the time of the first post-operative dose of study
medication, patients were connected to a patient-controlled
analgesia (PCA) device and morphine was self-administered
for at least 24 hours, as needed to control pain. The PCA
device was set to deliver 1 mg morphine with a 6-minute
lock-out period and a maximum total dose of 40 mg in
4 hours. If the dose was inadequate, the dose could have
been titrated incrementally up to 2 mg for a maximum
total dose of 50 mg in 4 hours. Patients were disconnected
from the PCA device when it was no longer needed;
defined as a time lapse since the last PCA morphine
dose ≥2 hours and a patient’s pain intensity reported
as ≤4 (0-to-10-point NRS). After disconnecting the
PCA device, patients could supplement their analgesia
with 2 oxycodone 5 mg tablets up to 4 times a day
(daily maximum of 80 mg oxycodone), through Day 7, in
addition to their study medication.
On Days 2 and 3, the first dose of study medication
was given approximately 24 and 48 hours after the initial
dose taken on Day 1, respectively. Patients received their
second and third doses of ibuprofen 600 mg or matching
placebo every 8 hours from the time of the first dose.
On Days 4 to 7, patients were switched to a first dose of
study medication at 8 a.m, with second and third doses
of ibuprofen 600 mg or matching placebo given every
6 hours, (i.e. 2 p.m. and 8 p.m.). There were 10 study
visits: Visit 1 (screening visit within 21 days of surgery
date); Visit 2 (postsurgery predose); Visit 3 (randomization);
Visit 4 was for database purposes only and was not a separ-
ate clinic/hospital visit; Visits 5–9 (days 3,4,5,6,7); Visit 10
(one day after last dose of study medication).
Surgical procedure
Knee replacement surgery was performed according to
local practice, but anesthesia was standardized using
either general or spinal anesthesia. General anesthesia
consisted of isoflurane, sevoflurane, or desflurane and
nitrous oxide. Spinal anesthesia consisted of up to
15 mg bupivacaine with no spinal opioids. All patients
received 4 mg of ondansetron IV during induction to
prevent postoperative nausea and vomiting. Propofol
was allowed at a dose of 2 to 3 mg/kg and fentanyl
was not to exceed a cumulative intra-operative dose of
10 ug/kg or a total cumulative dose of 500 ug, which-
ever was less. Infiltration of the wound with any local
anesthetic agent, including intra-articular analgesia, was
not permitted.
Study medication dosing
Patients were allocated at random based on a computer-
generated randomization schedule by an Interactive Voice
Response System (IVRS) on the day of admission for
surgery, to 1 of the 4 treatment options. The active medi-
cations and placebo were identical in appearance, size,
shape, and taste, ensuring proper blinding of patients,
investigator study staff, and sponsor staff, throughout
the study duration. Patients were required to stay in
hospital for at least 72 hours from the first dose of study
medication.
Efficacy measurements and hypotheses
The co-primary endpoints were Average Pain Intensity
Difference at Rest (as measured on a 0- to 10-point NRS)
over Days 1 to 3 and Average Total Daily Dose of Mor-
phine over Days 1 to 3. Other endpoints included Change
from Baseline in Average Pain Intensity at Rest (0- to 10-
point NRS) over Days 4 to 7, Average Total Daily Dose
of Morphine Consumed over Days 4 to 7, and Change
from Baseline in Average elicited Pain Intensity at Knee
Flexion over Days 1 to 3 and over Days 4 to 7.
The objectives of this study were to 1) demonstrate
that the analgesic effect of etoricoxib 90 mg or 120 mg,
administered once daily, is superior to placebo for the
treatment of pain following total knee replacement
orthopedic surgery (primary objective); 2) to demonstrate
that the analgesic effect of etoricoxib 90 mg or 120 mg,
administered once daily, is non-inferior to ibuprofen
1800 mg; and 3) to assess the safety and tolerability of
repeated doses of etoricoxib administered over a total
7-day time period in patients treated for pain follow-
ing total knee replacement orthopedic surgery.
To address these objectives, the primary hypotheses
were that: 1) the Average Pain Intensity Difference at
Rest over Days 1 through 3 in patients treated with etor-
icoxib 90 mg or 120 mg would be superior to placebo;
2) the Average Total Daily Dose of Morphine on Days 1
through 3 in patients treated with etoricoxib 90 mg or
120 mg would be less than in patients treated with pla-
cebo; and 3) etoricoxib 90 mg and 120 mg would be
generally safe and well tolerated. The secondary hypoth-
esis was that the Average Pain Intensity Difference at
Rest over Days 1 through 3 in patients treated with etor-
icoxib 90 mg or 120 mg would be non-inferior to that
of ibuprofen 1800 mg. Ibuprofen was included in the
study as an active comparator; therefore, there was no
planned statistical comparison for ibuprofen compared
with placebo.
Pain intensity at rest
Patients rated their pain at rest while in a supine pos-
ition. During the treatment period, patients recorded
Pain Intensity at Rest at 4 pre-specified time points
on Days 1 to 3 and at 2 pre-specified time points on
Days 4 to 7.
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Pain intensity at knee flexion
Patients rated Pain Intensity with Knee Flexion, on a
0- to 10-point NRS; a baseline measurement on the
knee that underwent joint replacement was taken prior
to administering the first dose of study medication. The
Pain Intensity with Knee Flexion assessment was done
2 hours after the first dose of study medication on Days
1 to 3 and once between 12 to 4 pm on Days 4 to 7.
Knee flexion was performed passively, to 90 degrees.
Opioid use
The Average Total Daily Dose of Morphine (morphine
equivalent) used during Days 1 to 3 was a co-primary
endpoint and the average Total Daily Dose of Morphine
(morphine equivalent) used during Days 4 to 7 was a
tertiary endpoint for the study. The total included all
doses of morphine (delivered by PCA and IV bolus),
oxycodone 5 mg, and any other opioids.
The Recovery Index (RI), a 49-item questionnaire, was
included to monitor patient recovery postoperatively.
The Opioid Side Effects Scale is a 22-item subscale of
the RI-49 that was used to assess patient tolerance of
opioid side effects. Patients completed the RI Scale on
Days 2 to 7 at bedtime. Patients also completed the RI
Scale at the discontinuation visit if they had not com-
pleted the RI Scale in the past 12 hours.
Other efficacy endpoints included Average Pain Inten-
sity Difference at Rest (0- to 10-point NRS) over Days 4
to 7, Average Total Daily Dose of Morphine (morphine
equivalent) over Days 4 to 7, Average Elicited Pain In-
tensity Difference at Knee Flexion (0- to 10-point NRS)
over Days 1 to 3 and Average Elicited Pain Intensity Dif-
ference at Knee Flexion (0- to 10-point NRS) over Days
4 to 7.
Responder analyses
Post hoc responder analyses were conducted to provide
further insight on the effect of etoricoxib compared with
placebo by evaluating the level of improvement achieved
from Days 1 to 3 and from Days 4 to 7, consistent with
the Initiative on Methods, Measurement, and Pain As-
sessment in Clinical Trials (IMMPACT) recommenda-
tions for reporting on clinical trials [13]. Percent change
from baseline over Days 1 to 3 and percent change from
baseline over Days 4 to 7 were calculated based on the
Pain Intensity at Rest (0- to-10 point NRS) and the Pain
Intensity at Knee Flexion (0- to-10 point NRS). The
percentages of patients reaching various degrees of im-
provement (i.e., percent reductions) in the Pain Intensity
at Rest (0-to-10 point NRS) and in the Pain Intensity at
Knee Flexion (0-to-10 point NRS) were plotted by treat-
ment groups. Because Pain Intensity at Rest was measured
on a 0- to 10-point NRS scale, a negative change from
baseline indicated an improvement from baseline. Patients
who dropped out at any day of Days 1 to 3 or of Days 4
to 7 for any reason were assigned an improvement of
0% for the corresponding responder analysis.
Subgroup analyses
In order to explore the consistency of the treatment ef-
fects with respect to baseline pain intensity (moderate
versus severe pain) and type of anesthesia (spinal versus
general) patients received for the surgery, subgroup ana-
lyses were performed for the 2 co-primary endpoints.
Safety measurements
Safety and tolerability were assessed through physical
examination, vital signs, laboratory tests (CBC, serum
chemistry, urinalysis, and urine pregnancy tests). In addition,
this study was subject to a prespecified blinded, adjudication
procedure for potential thromboembolic, investigator-
reported serious cardiovascular AEs.
Safety assessments were summarized using a tiered
approach [14]. Tier 1 AEs were prespecified and in-
cluded edema-related AEs; hypertension-related AEs; a
composite AE of congestive heart failure, pulmonary
edema or cardiac failure; and opioid-related AEs (i.e.,
nausea, vomiting, constipation, somnolence, respiratory
depression, urinary retention, and ileus). Tier 2 AEs in-
cluded any adverse event not prespecified as Tier 1 that
occurred in ≥4 patients in any one of the treatment
groups. Tier 3 AEs included change from baseline in
vital signs, serum creatinine, and estimated glomerular
filtration rate; and any adverse event not prespecified as
Tier 1 or Tier 2 that occurred in <4 of patients in all of
the treatment groups.
Statistical analyses
The study plans called for 713 patients to be randomized
in a fully concealed manner (i.e. blinded to patient, study
staff, sponsor personnel, etc.) to 1 of 4 treatments in a
9:9:9:4 ratio: etoricoxib 120 mg (n = 207), etoricoxib
90 mg (n = 207), ibuprofen 1800 mg (600 mg TID) (n = 207)
or placebo (n = 92), with a total of 776 ultimately ran-
domized. For the co-primary endpoint of Average Pain
Intensity at Rest over Days 1 to 3, this sample size was
predicted to have > 99% power (α = 0.05, 2-tailed) to
detect a significant difference between etoricoxib and
placebo of 2 points, with an assumed standard deviation
of 3.08. For the second co-primary endpoint, Average
Total Daily Dose of Morphine over Days 1 to 3, the study
was powered at 93% to detect a 25% reduction in mor-
phine use (α = 0.05, 2-tailed) between etoricoxib and pla-
cebo doses.
For the non-inferiority comparison of etoricoxib (120 mg,
90 mg) to ibuprofen 1800 mg with respect to the average
pain intensity difference over Days 1 to 3, with an assumed
standard deviation of 3.08, the sample sizes were predicted
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to have 91% power (1-sided, α =0.025) to declare that
etoricoxib was at least as effective as ibuprofen 1800 mg,
given a non-inferiority bound of 1 point on a 0–10 NRS.
To preserve the experimental-wise type-I error rate for
the co-primary and secondary hypotheses, the compari-
sons of the 2 etoricoxib doses with placebo were con-
ducted in a step-down manner. Etoricoxib 120 mg was
compared with placebo with the co-primary endpoints
first, and, only if it was shown to be superior to placebo
at the 5% critical level (2-sided) for each of the 2 co-
primary endpoints was the 90-mg dose compared with
placebo, also at the 5% critical level for each of the co-
primary endpoints (2-sided). Because both co-primary
endpoints had to be significant (α = 0.05, two-sided) in
order to declare that an etoricoxib dose (120 mg, 90 mg)
was superior to placebo, no multiplicity adjustment was
needed for the co-primary endpoints for the given dose.
This step-down testing procedure controls the type-I error
rate at 5% for the testing of both doses against placebo for
the co-primary hypotheses. The secondary hypothesis of
the non-inferiority of an etoricoxib dose to ibuprofen
1800 mg was conducted with regard to the Average Pain
Intensity Difference at Rest (0- to 10-point NRS) over
Days 1 to 3 only if that same etoricoxib dose was shown
to be superior to placebo with respect to both of the
co-primary endpoints at the critical 5% level.
The Full Analysis Set (FAS) population, including
all randomized patients who received at least 1 dose
of study medication and had at least 1 post-randomization
measurement, was used for the primary efficacy analysis.
The Per-Protocol (PP) population was used as a support-
ive analysis.
A longitudinal data analysis (LDA) [15] was used to
analyze between-group differences in Average Pain In-
tensity difference at Rest (0- to 10-point NRS) over Days
1 to 3 and over Days 4 to 7 and Average Elicited Pain
Intensity difference at knee flexion (0- to 10-point NRS)
over Days 1 to 3 and over Days 4 to 7. This LDA model
included both baseline and post-baseline measurements
as response variables. The LDA model included terms
for treatment, time, and the interaction of time by treat-
ment, with restriction of the same baseline mean across
treatment groups (due to randomization). The LDA model
also adjusted for baseline pain intensity and anesthesia type
used for surgery. A longitudinal ANOVA was used to
analyze between-group differences in the Average Total
Daily Dose of Morphine over Days 1 to 3 and morphine
(morphine equivalent) over Days 4 to 7 and the Recovery
Index Opioid Side Effects Score on each day from Day 2
to 7. The longitudinal ANOVA model included terms
for baseline pain intensity, anesthesia types, treatment,
time, and the interaction of time by treatment. Log-
transformation was applied to the total daily morphine
use to bring them to a relative scale. The average total
daily dose of morphine over Days 1 to 3 and Days 4 to
7 was estimated from the longitudinal ANOVA model
and back-transformed as LS geometric means.
A Cox proportional hazards regression model was used
to analyze time to last dose of morphine administered via
PCA device; between-group comparisons were assessed by
risk ratios (with 95% confidence intervals [CIs]). Time-to-
event endpoints were plotted using Kaplan-Meier curves.
The All Patients as Treated (APaT) population was
used for safety analysis and included all randomized pa-
tients who received ≥1 dose of study drug and had a
change from baseline in laboratory measurements.
For the responder analyses, the differences between
each dose of etoricoxib and the comparators and between
the two doses regarding the percentages for patients
achieving a ≥20%, ≥50%, and ≥70% improvement from
baseline based on the Pain Intensity at Rest over Days 1
to 3 were tested separately using the Miettinen and Nur-
minen method, an unconditional, asymptotic method with
α = 0.050 (2-sided) [16]. For the subgroup analyses, the
evaluation was primarily through the examination of the
LS means for the treatment groups across the different
categories or levels of the pre-existing factor and the asso-
ciated nominal 95% confidence intervals.
Safety analyses
The analysis of safety results followed a tiered approach;
the tiers differed with respect to the analyses performed.
Safety parameters or AEs of special interest that were
identified a priori were considered Tier 1 safety end-
points and were subject to inferential testing for statistical
significance. P-values (Tier 1 only) and 95% CIs (Tier 1
and Tier 2) were provided for between-treatment differ-
ences in the percentage of patients with events; these ana-
lyses were performed using the Miettinen and Nurminen
method [16].
Results
Patients
Of the 925 patients screened for the study, 776 patients
met the study inclusion criteria and were randomized to
placebo (N = 98), etoricoxib 90 mg (N = 224), etoricoxib
120 mg (N = 230), or ibuprofen (N = 224) (Figure 1). The
primary reasons for exclusion from the trial included
failure to meet inclusion criteria and patient withdrawal.
There was one study site that failed audit, and therefore
the 6 patients from that site were excluded from final
analyses. In total, 702 (90.5%) patients completed the
study. The rates of completion and discontinuation were
similar for all treatment groups. The primary reasons for
study discontinuation were related to adverse experi-
ences and patient withdrawal (Figure 1).
All treatment groups were similar with respect to base-
line demographics (Table 1). Overall, patients underwent
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Did not take any dose 
No postoperative 
efficacy measure 
Failed Audit
Continuous infusion 
of morphine
N = 96 (98%) N = 211 (94.2%) N = 224 (97.4%) N = 216 (96.4%)
Placebo
N=98
Etoricoxib 90 mg
N = 224
Screened
N=925
Randomized 
N = 776
Etoricoxib 120 mg
N = 230
Ibuprofen 1800 mg
N = 224
Excluded from
Full analysis Set
N = 85 (86.7%)
Included in
Full analysis Set
Completed
Discontinued
= 0
= 2 (2.0%)
= 0
= 0
Adverse Event 
Lack of Efficacy 
Physician Decision
Protocol violation
Withdrawal by 
Subject
= 5 (5.1%)
= 2 (2.0%)
= 0 (0.0%)
= 0
= 6 (6.1%)
N = 198 (88.4%)
Adverse Event 
Lack of Efficacy 
Physician Decision
Protocol violation
Withdrawal by 
Subject
= 15 (6.7%)
= 2 (0.9%)
= 0
= 3 (1.3%)
= 6 (2.7%)
N = 216 (93.9%)
Adverse Event 
Lack of Efficacy 
Physician Decision
Protocol violation
Withdrawal by 
Subject
= 8 (3.5%)
= 1 (0.4%)
= 1 (0.4%)
= 0
= 4 (1.7%)
N = 203 (90.0%)
Adverse Event 
Lack of Efficacy 
Physician Decision
Protocol violation
Withdrawal by 
Subject
= 10 (4.5%)
= 2 (0.9%)
= 1 (0.4%)
= 4 (1.8%)
= 4 (1.8%)
Excluded
Adverse Event 
Lost to follow-up
Protocol violation
Screen failure
Withdrawal by 
Subject
Other
(N = 149)
= 2 (1.3%)
= 1 (0.7%)
= 10 (6.7%)
= 89 (59.1%)
= 38 (25.5%)
= 9 (6.0%)
Did not take any dose 
No postoperative 
efficacy measure 
Failed Audit
Continuous infusion 
of morphine
= 1 (0.5%)
= 8 (3.6%)
= 3 (1.3%)
= 1 (0.5%)
Did not take any dose 
No postoperative 
efficacy measure 
Failed Audit
Continuous infusion 
of morphine
= 0
= 4 (1.7%)
= 1 (0.4%)
= 1 (0.4%)
Did not take any dose 
No postoperative 
efficacy measure 
Failed Audit
Continuous infusion 
of morphine
= 1 (0.5%)
= 5 (2.2%)
= 2 (0.9%)
= 0
Figure 1 CONSORT Diagram showing patient accounting.
Table 1 Baseline characteristics
Placebo Etoricoxib 90 mg Etoricoxib 120 mg Ibuprofen 1800 mg
N = 98 N = 224 N = 230 N = 224
Female n (%) 56 (57.1) 134 (59.8) 139 (60.4) 152 (67.9)
Age
Mean [yr (SD)] 65.2 (7.9) 65.7 (8.5) 64.7 (8.1) 66.0 (8.1)
Median 64.5 66.0 64.0 66.0
Range 43 - 81 37 - 84 44 - 86 38 – 84
Height in cm (SD) 167.1 (10.6) 166.9 (10.8) 168.1 (10.6) 165.8 (10.6)
Body Weight in kg (SD) 85.9 (17.3) 86.2 (17.6) 85.4 (16.2) 84.4 (16.6)
Body Mass Index (SD) 30.6 (4.7) 30.8 (5.0) 30.2 (4.7) 30.6 (4.7)
Duration of Surgery in hours (SD) 1.4 (0.5) 1.4 (0.5) 1.4 (0.5) 1.4 (0.5)
Baseline Pain Intensity at Rest NRS (SD)
Mean Score (SD) 7.1 (1.8) 7.0 (1.8) 7.1 (1.8) 6.9 (1.7)
Mild Pain (Score: 0–4) n (%) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.4)
Moderate Pain (Score 5–7) n (%) 60 (61.2) 137 (61.2) 135 (58.7) 140 (62.2)
Severe Pain (Score 8–10) n (%) 38 (38.8) 85 (37.9) 94 (40.9) 83 (37.1)
Anesthesia Type n (%)
General 38 (38.8) 83 (37.1) 90 (39.1) 81 (36.2)
Spinal 60 (61.2) 141 (62.9) 140 (60.9) 142 (63.4)
Other 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
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surgery lasting a mean of 1.4 hours and had a mean base-
line pain intensity score at rest (0- to 10-point NRS) of 7.0
(after surgery and before randomization to study medica-
tion). A majority of patients (62.2%) underwent surgery
after spinal anesthesia.
Efficacy endpoints
Average pain intensity at rest
Both etoricoxib doses (120 mg and 90 mg) were superior
to placebo (p = 0.018 and p = 0.009, respectively) and
also non-inferior to ibuprofen 1800 mg daily. In the co-
primary endpoint of change from baseline in Average
Pain Intensity at Rest over Days 1 to 3, the improve-
ments seen for the 2 etoricoxib dose groups (120- and
90-mg) were similar (Table 2; Figure 2A).
Morphine utilization
Both etoricoxib doses (120 mg and 90 mg) were superior
to placebo in the co-primary endpoint of average total
daily dose of morphine over Days 1 to 3 (p < 0.001);
morphine consumption was 31% and 34% less per day,
averaged over the first 3 days, in patients treated with
etoricoxib 120 mg and 90 mg, respectively, vs. placebo
(Table 2). No notable differences in average daily mor-
phine consumption over Days 1 to 3 occurred between
etoricoxib 120 mg (−4.15 mg vs. placebo) or etoricoxib
90 mg (−4.53 mg vs. placebo) and ibuprofen 1800 mg
(−4.58 mg vs. placebo). The morphine consumption
amounts among the patients administered etoricoxib 120
and 90 mg were approximately 15% less than placebo on
Day 1 and this difference increased to ~25% on Day 2 and
between 45% to 55% on Days 3 to 7 (Figure 2B).
Pain on movement
When averaged over Days 1 to 3, etoricoxib 120 mg and
90 mg showed greater reductions from baseline in Pain
Elicited with Knee Flexion, with reductions of 0.46 and
0.37 units on a 0-to-10 NRS scale, respectively, com-
pared with placebo; however, the differences were not
statistically significant (nominal p values ≥0.057).
Averaged over Days 4 to 7, both etoricoxib dose groups
(120 mg, 90 mg) showed nominally significant greater re-
duction from baseline as compared with placebo on Pain
Intensity with Knee Flexion.
There were no notable differences observed when
comparing etoricoxib doses (120 mg, 90 mg) with ibu-
profen 1800 mg in average change from baseline in Pain
Intensity at Knee Flexion over Days 1 to 3; however,
greater differences between etoricoxib 120 mg and ibu-
profen were observed over Days 4 to 7 in favor of etori-
coxib 120 mg (i.e., exclusion of 0 in the confidence
intervals) (Figure 2C).
Responder analyses
Analyses were performed to optimize assay sensitivity
and identify patients who attained levels of pain reduc-
tion consistent with being clinically important (i.e., 30%,
50%, and 70% improvement). Figure 3 demonstrates that
greater improvements and greater separation from pla-
cebo were achieved with study medication for both
Average Pain Intensity at Rest (Figures 3A and B) and
Average Pain Intensity at Knee Flexion (Figures 3C and
D) for the Day 4 to 7 period as compared with the Day 1
to 3 period.
Subgroup analyses – average pain intensity at rest and
morphine consumption by subgroups of patients with
different levels of baseline pain severity and type of
anesthesia
Patients who had severe pain at baseline had a greater
improvement from baseline than those who began the
study with moderate pain at baseline. However, the rank-
ing of improvement among the active treatments (etori-
coxib and ibuprofen) and placebo were consistent across
these subgroups (Figure 4A).
Patients who received general anesthesia reported
higher levels of baseline pain at the time of random-
ization. Further, the improvement from baseline was also
larger for patients receiving general anesthesia as com-
pared with those who had spinal anesthesia; this was true
across all treatments and the rank of the treatment differ-
ences from placebo for the 3 active treatment groups
(etoricoxib and ibuprofen) was also consistent across the
anesthesia subgroups (Figure 4B).
Interestingly, there was no important difference in the
amount of morphine consumed based on baseline pain
severity (Figure 4C). There was numerically less con-
sumption of morphine in patients receiving general
anesthesia as compared with spinal anesthesia, for the
active therapies, although the placebo groups had similar
morphine consumption (Figure 4D).
Safety and tolerability
The incidence of clinical AEs was generally similar among
the placebo, etoricoxib (120 mg, 90 mg), and ibuprofen
groups; overall, few serious AEs (2.3%) and drug-related
AEs (4.5%) occurred and few patients discontinued (4.8%)
for any reason, including safety or tolerability. There was
a numerically higher percentage of patients with opioid-
related AEs in the placebo group compared with the active
treatments. The etoricoxib 120 mg group also had the
lowest proportion of patients with bleeding-related AEs
among the treatment groups (Table 3).
Overall, 6 confirmed thromboembolic events occurred
in 5 patients during the treatment period. There were 2
events (cardiac arrest and transient ischemic attack) in 1
patient in the placebo group. Two patients in the
Rawal et al. BMC Musculoskeletal Disorders 2013, 14:300 Page 7 of 14
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Table 2 Summary of efficacy endpoints
Endpoints Placebo Etoricoxib 90 mg p-Value vs. placebo Etoricoxib 120 mg p-Value vs. placebo Ibuprofen 1800 mg*
Primary endpoints Value (95% CI)
LS Mean Change from Baseline Average Pain Intensity at
Rest over Days 1–3 (0–10 point NRS)
−3.39 (−3.74, -3.04) −3.93 (−4.17, -3.69) p = 0.018 −3.87 (−4.11, -3.64) p = 0.009 −3.83 (−4.07, -3.59)
LS Geometric Mean Total Daily Dose of Morphine Over
Days 1 to 3 mg
13.4 (11.2, 16.0) 8.87 (7.88, 9.97) p < 0.001 9.25 (8.26, 10.4) p < 0.001 8.82 (7.85, 9.91)
Raw Geometric Mean Total Daily Dose Over Days 1 to 3 13.5 8.84 N/A 9.26 N/A 8.83
Other endpoints
LS Mean Change from Baseline Average Pain Intensity at
Rest over Days 4–7 (0–10 point NRS)
−4.03 (−4.39, -3.67) −4.74 (−5.00, -4.49) p < 0.001 −4.92 (−5.16, -4.67) p < 0.001 −4.70 (−4.95, -4.45)
Postoperative Morphine Consumption (mg) 3.43 (2.69, 4.36) 1.72 (1.46, 2.02) N/A 1.70 (1.46, 1.99) N/A 2.06 (1.76, 2.41)
LS Geometric Mean Total Daily Dose Over Days 4 to 7
Raw Geometric Mean Total Daily Dose Over Days 4 to 7 3.49 1.71 N/A 1.70 N/A 2.06
LS Mean Change from Baseline in Pain Intensity at Knee
Flexion over Days 1 to 3 (0- to 10-point NRS)
−1.59 (−2.00, -1.17) −1.96 (−2.24, -1.68) p = 0.057 −2.05 (−2.32, -1.78) p = 0.129 −2.00 (−2.28, -1.72)
LS Mean Change from Baseline in Pain Intensity at Knee
Flexion over Days 4 to 7 (0- to 10-point NRS)
−3.61 (−4.05, -3.18) −4.78 (−5.08, -4.48) p < 0.001 −5.16 (−5.45, -4.87) p < 0.001 −4.56 (−4.85, -4.26)
*p-values were not calculated for the comparison of ibuprofen vs. placebo.
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etoricoxib 90 mg group and 2 patients in the etoricoxib
120 mg group had cardiovascular events; in both groups,
there was a patient with a pulmonary embolism and a
patient with acute myocardial infarction. No confirmed
thromboembolic events occurred in the ibuprofen group.
Of note, both patients with myocardial infarction had
pre-existing risk factors.
Recovery index opioid side effect scale
The LS mean score for the Recovery Index Opioid Side
Effects Scale showed that both etoricoxib doses (120 mg,
90 mg) were consistently lower (patients reported less
opioid-related side effects) than those on placebo, over
the 7 days of the study; the LS mean scale scores were
similar between the 2 etoricoxib dose groups and ibu-
profen 1800 mg group (Figure 5).
Discussion
Etoricoxib is a selective COX-2 inhibitor that has shown
efficacy in the treatment of acute pain [11]. This ran-
domized, double-blind trial evaluated the role of 2 doses
of etoricoxib, 90 mg and 120 mg, in a multimodal anal-
gesic regimen in patients who underwent unilateral knee
replacement surgery. The goal of post-operative pain
management is to improve patient satisfaction, reduce
the length of the hospital stay, and overall facilitation of
the rehabilitation process by providing pain relief and re-
ducing opioid-related AEs [17].
In this trial, patients were provided with morphine
through a PCA pump on the first day and opioids on
subsequent days; etoricoxib 90 mg, etoricoxib 120 mg,
ibuprofen 1800 mg, and placebo were provided to these
patients in addition to the PCA pump and opioids. Al-
though patients were able to titrate morphine use to the
level of desired pain relief in all treatment groups, pa-
tients given etoricoxib demonstrated significantly lower
pain intensity than patients given placebo and standard
opioid-based analgesic treatment. Additionally, consump-
tion of opioids was reduced in association with a reduc-
tion in patient-reported opioid negative consequences.
The etoricoxib (120 mg, 90 mg) groups were non-inferior
to ibuprofen 1800 mg/day for both the pain and morphine
consumption endpoints (no formal testing was done to
compare ibuprofen and placebo). The benefits of etoricoxib
were observed consistently across multiple endpoints, in-
cluding Pain Intensity at Rest, Pain Intensity with Knee
Flexion, Total Daily Dose of Morphine consumption, and
Opioid Side Effects Scale scores.
The results reported here are consistent with the level
of pain relief reported in a recent meta-analysis of previ-
ous trials of selective COX-2 inhibitors with a total of
571 patients; the reduction in pain scores in the meta-
analysis on a 0–10 visual analog scale ranged from −0.40
to −1.31 over the first 24 hours and 0.01 to −1.04 from
24 to 48 hours [18]. The differences from placebo in pain
intensity for the present trial were −0.54 and −0.48 units
for etoricoxib 90 and 120 mg, respectively, and −0.44 units
with ibuprofen. The reduction of morphine in the meta-
analysis ranged from −0.03 to −7.00 mg while the reduction
in our trial was −4.53 and −4.24 mg for etoricoxib 90
and 120 mg, respectively, and −4.58 mg for ibuprofen
[18]. Given the large size of the present trial, with 773 pa-
tients and its multi-site, multi-country conduct, the results
would be expected to be more generalizable than smaller,
regionally conducted trials evaluating analgesics in this
clinical setting.
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A Average Pain Intensity at Rest over 7 days
B Postoperative Morphine Consumption over 7 days
C Average Pain Intensity at Knee Flexion over 7 days
Placebo
Etoricoxib 90 mg
Etoricoxib 120 mg
Ibuprofen 1800 mg
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Figure 2 Co-primary efficacy endpoints over 7 Days. Panel A
shows Average Pain Intensity at Rest over 7 days. Panel B shows
Postoperative Morphine Consumption over 7 days. Panel C shows
Average Pain Intensity at Knee Flexion over 7 days.
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The results of the present trial confirm the results of
an earlier, smaller trial examining the 120-mg dose of
etoricoxib in the treatment of patients after knee or hip
surgery; in that study, etoricoxib was superior to placebo
and similar to the traditional NSAID, controlled-release
naproxen sodium 1100 mg [11]. Etoricoxib 90 mg has
been compared to etoricoxib 120 mg in two other prior
post-operative pain settings. It was evaluated in the
post-operative pain setting using third-molar extraction
over a 3-day treatment period [19]. These two doses
were also evaluated in patients undergoing total abdom-
inal hysterectomy surgery over a treatment period of
5 days that included pre-operative dosing [20]. In those
studies, etoricoxib 90 mg performed similarly to the
120-mg dose according to the primary endpoints used,
although there was some evidence of separation of the
two doses when evaluating efficacy upon movement
endpoints in the abdominal hysterectomy trial [19,20].
As a methodologically interesting point, the benefits of
etoricoxib became more evident beyond the first 2 days
after surgery; the period of Days 4 to 7 demonstrated
greater separation from placebo as compared with Days
1 to 3. This finding may have been due to the very high
pain burden early postoperatively, and the larger re-
quirement for morphine; the differences in reduction of
pain intensity between etoricoxib and placebo increased
as the use of opioids decreased. The improvements from
baseline in Pain Intensity at Rest for both etoricoxib
groups (120 mg, 90 mg) were numerically but not statis-
tically greater than that of placebo on Day 1, when mor-
phine use was the greatest. However, these differences
increased over time for both etoricoxib groups, com-
pared with placebo, over Days 2 to 7, as the pain burden
and the subsequent morphine use declined. Morphine
consumption was approximately 15% less for both etori-
coxib groups (120 mg, 90 mg), compared with placebo,
on Day 1, increasing to approximately 25% less on Day 2
and between 34% to 55% less on Days 3 to 7 in the etori-
coxib groups. This pattern of greater separation from
placebo over time was also observed in the Average Pain
Intensity with Knee Flexion endpoint, an endpoint that
also increased the pain stimulus as compared with asses-
sing pain at rest. The etoricoxib 120-mg group showed
greater reduction from baseline in average Pain Intensity
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Figure 3 Responder Analyses showing the percent of patients who improved by different percent levels of pain intensity reduction at
rest on Days 1 to 3 (Panel A) and Days 4 to 7 (Panel B) and at knee flexion on Days 1 to 3 (Panel C) and Days 4 to 7 (Panel D).
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with Knee Flexion compared with ibuprofen 1800 mg
over the Day 4 to 7 interval.
This trial was conducted prior to the recommenda-
tions by the IMMPACT group for the evaluation of pain
in trials [13]. We therefore performed post hoc responder
analyses consistent with IMMPACT recommendations.
These analyses demonstrated greater separation for the
Average Pain Intensity with Knee Flexion endpoint among
patients who achieved >70% pain improvement for etori-
coxib 120 mg vs. etoricoxib 90 mg, ibuprofen, or placebo.
Subgroup analyses demonstrated that both subgroups
of patients, those with severe pain and those patients
with moderate pain, achieved a reduction in Pain Intensity
at Rest as well as having a reduction in morphine con-
sumption with etoricoxib as compared with placebo. Base-
line pain was higher in patients with general anesthesia
compared with spinal anesthesia; this observation may be
important for future research with analgesic compounds
as increased baseline pain may improve assay sensitivity
and better identify any treatment differences. In this
study, a higher proportion of patients had spinal anesthesia;
with regard to assay sensitivity over Days 1 to 3, a larger
difference from placebo was observed for general anesthesia
for the endpoint of LS Geometric Mean Morphine
Consumption.
The incidence of clinical AEs was generally similar
among the placebo, etoricoxib (120 mg, 90 mg), and
ibuprofen groups. There were no notable differences in
serious AEs or discontinuations from AEs. Thrombo-
embolic events are known perioperative complications
of total knee replacement surgery, with preventative
therapy recommended in most guidelines [21-23]. These
events are also of interest for the evaluation of traditional
NSAIDs and COX-2 selective inhibitors [24]. The incidence
4 6 8 10 12 14 16 18 20
Moderate
Pain
Severe
Pain
Morphine (mg) Consumption
(LS Geometric Mean, 95% CI)
C Morphine Consumption by Baseline Pain Severity
4 6 8 10 12 14 16 18
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D Morphine Consumption by Type of Anesthesia
-7.0 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0
Moderate
Pain
Severe
Pain
Average Pain Intensity at Rest
Change from Baseline (LS Mean, 95% CI) 
A  Pain Intensity by Baseline Pain Severity
General
Anesthesia
Spinal
Anesthesia
B  Pain Intensity at Rest by Anesthesia Type
-6.00 -5.00 -4.00 -3.00 -2.00
Morphine (mg) Consumption
(LS Geometric Mean, 95% CI)
Average Pain Intensity at Rest
Change from Baseline (LS Mean, 95% CI) 
Placebo
*Including associated 95% CIs
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Figure 4 Subgroup analyses for the co-primary endpoints of patients who had moderate pain vs. severe pain (Panels A and B) and for
patients who received general anesthesia vs. spinal anesthesia (Panels C and D). Both LS Geometric Means (solid squares) and associated
95% CIs as well as Arithmetic Means (open circles) are shown.
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of myocardial infarction and pulmonary embolism in this
study was similar to the incidence observed in a previous
analysis of 10,244 patients who underwent primary total
hip or knee arthroplasty [25]. Overall, the rate of cardio-
vascular AEs in this trial was low, was deemed unrelated
to study medication by the investigators, and was con-
sistent with the background rate of events postopera-
tively in this patient group. However, patients with certain
cardiovascular comorbidities and risk factors were ex-
cluded from this trial.
Bleeding-related AEs and wound infection AEs were
similar among both the placebo and the treatment groups.
The evaluation of patient reporting of adverse experiences
related to opioids, as measured by patient-reported Re-
covery Index Opioid Side Effects Scale demonstrated an
important reduction in opioid-related AEs in the active
Table 3 Summary of safety and tolerability
Placebo Etoricoxib Etoricoxibn Ibuprofen
N = 98 90 mg 120 mg 1800 mg
n(%) N = 222 N = 230 N = 223
n(%) n(%) n(%)
One or more AEs 68 (69.4) 141 (63.5) 144 (62.6) 134 (60.1)
Discontinued due to AEs 5 (5.1) 14 (6.3) 8 (3.5) 10 (4.5)
Drug-related AEs 3 (3.1) 12 (5.4) 11 (4.8) 9 (4.0)
Discontinued due to Drug-related AEs 1 (1.0) 2 (0.9) 1 (0.4) 3 (1.3)
Serious AEs 4 (4.1) 5 (2.3) 4 (1.7) 5 (2.2)
Discontinued due to Serious AEs 1 (1.0) 4 (1.8) 2 (0.9) 2 (0.9)
Tier 1 AEs
CHF, pulmonary edema, or cardiac failure composite 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0)
Edema-related 4 (4.1) 2 (0.9) 4 (1.7) 4 (1.8)
Hypertension-related 3 (3.1) 8 (3.6) 3 (1.3) 7 (3.1)
Opioid-related 41 (41.8) 77 (34.7) 84 (36.5) 81 (36.3)
Tier 2 AEs (AEs that occurred in ≥4 patients in any one treatment group)
Constipation 13 (13.3) 26 (11.7) 33 (14.3) 30 (13.5)
Dyspepsia 8 (8.2) 5 (2.3) 9 (3.9) 10 (4.5)
Nausea 31 (31.6) 50 (22.5) 56 (24.3) 53 (23.8)
Vomiting 13 (13.3) 27 (12.2) 30 (13.0) 33 (14.8)
Edema peripheral 4 (4.1) 2 (0.9) 4 (1.7) 4 (1.8)
Pyrexia 27 (27.6) 13 (5.9) 25 (10.9) 23 (10.3)
Anaemia (postoperative) 4 (4.1) 11 (5.0) 6 (2.6) 6 (2.7)
Dizziness 3 (3.1) 14 (6.3) 15 (6.5) 14 (6.3)
Headache 3 (3.1) 9 (4.1) 7 (3.0) 6 (2.7)
Insomnia 11 (11.2) 23 (10.4) 21 (9.1) 17 (7.6)
Oliguria 4 (4.1) 2 (0.9) 6 (2.6) 4 (1.8)
Hyperhidrosis 4 (4.1) 14 (6.3) 14 (6.1) 11 (4.9)
Pruritus 4 (4.1) 19 (8.6) 15 (6.5) 17 (7.6)
AEs of Interest in Postoperative Patients
Bleeding-related AEs 7 (7.1) 16 (7.2) 11 (4.8) 14 (6.3)
Wound infection-related AEs 0 (0.0) 4 (1.8) 1 (0.4) 5 (2.2)
Wound-related AEs 2 (2.0) 1 (0.5) 2 (0.9) 2 (0.9)
All Confirmed Thromboembolic Events
Myocardial Infarction 0 (0.0) 1 (0.5) 1 (0.4) 0 (0.0)
Transient Ischemic Attack 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pulmonary Embolism 0 (0.0) 1 (0.5) 1 (0.4) 0 (0.0)
Cardiac Arrest 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
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treatment groups compared with the placebo group,
documenting the intended benefit of multimodal pain
care postoperatively. Because patients were permitted to
use morphine/oxycodone ad libitum for pain control,
achieving the simultaneous reduction in pain intensity
at rest and a reduction in opioid use, with less patient-
reported opioid negative experiences, reinforces the
tenets of multimodal care and suggests that adding
etoricoxib to standard opioid therapy has distinct, measure-
able advantages compared with an opioids-alone approach.
This was a multicenter study conducted in several
countries; research has recently shown increasing the
number of countries and sites increases the study vari-
ability, leading to different estimates of treatment effect-
iveness in osteoarthritis patients [26]. In the total knee
replacement acute pain setting, an increase in study vari-
ability could occur due to different operation procedures,
different anesthesia, and different postoperative care de-
pending on standard procedures at individual sites and
countries, which could confound results. An additional
limitation for this study was that it was not powered to
evaluate differences in bleeding risk between etoricoxib
and ibuprofen given postoperatively, nor was it powered
to detect differences in risk for cardiovascular events.
Nevertheless, the present trial is an important contri-
bution to the literature for NSAIDs and selective COX-2
inhibitors in the post-operative setting due to several
unique aspects. It is among the largest single trials con-
ducted to evaluate acute pain in a postoperative setting
over a period of 7 days with a 21-day follow-up period;
notably, it is larger than a recent metaanalysis of all prior
trials combined [18]. The 49-item Recovery Index and
the 22-item Opioid Side Effects Scale are novel approaches
for evaluating patient recovery. Finally, despite the afore-
mentioned limitations due to the multicenter, multinational
conduct, the completion of this trial demonstrates that
large trials evaluating postoperative care across large geo-
graphic regions is possible and shows that the results
are applicable across different nations and cultures des-
pite widely different therapeutic regimens.
Conclusions
In summary, in the treatment of pain following a unilat-
eral total knee replacement, etoricoxib, at doses of 90 mg
or 120 mg, administered postoperatively and then daily
for the next 6 days on a background of opioid use resulted
in greater pain control in this study as compared with
placebo (representing opioid use alone), as evidenced by
improvements in pain intensity at rest as well as leading
to a reduction in opioid use, with its attendant reduction
in patient-reported adverse experiences from opioids. The
improvements in the etoricoxib 120- and 90-mg groups
were non-inferior to the ibuprofen 1800 mg group. Im-
portantly, it was found that both etoricoxib 90 mg and
120 mg doses had a similar tolerability and safety profile
to placebo with better patient-reported tolerability on the
opioid side effects scale.
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